HitGen Pays $25 Million to Acquire Vernalis, a UK Discovery CRO, from Ligand

HitGen will acquire Vernalis Limited, a Cambridge , UK CRO, from Ligand Pharma for $25 million. HitGen, a Chengdu small molecule drug development CRO, said its operations are a good fit with Vernalis' expertise in fragment and structure-based drug discovery research. HitGen has built DNA-encoded chemical libraries (DELs) that contain billions of novel drug-like small molecule and macrocycle compounds and established discovery partnerships with more than 50 global biopharmas. More details.... Stock Symbols: (SHA: 688222) (NSDQ: LGND) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.